BIAF MEXC RealStocks
Own real BIAF shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-17 11:23:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
bioAffinity Technologies, Inc. (BIAF) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $2.12, with a market capitalization of $4.00M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.96 to $80.70. This page covers its latest market performance, valuation, price trends and company information.
$4.00M | |
$2.13 | |
$2.13 | |
$2.00 | |
$2.00 | |
107.00 | |
3.61M | |
-- | |
$80.70 | |
$1.96 | |
-- | |
-- |
bioAffinity Technologies, Inc. (BIAF) is trading at $2.12 in pre-market trading as of 2026-11-17 10:18:00, up 6.20% ($0.12) from the previous close of $2.00
Pre-market trading shows how investors are pricing BIAF before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, bioAffinity Technologies, Inc. (BIAF) moved from $2.72 to $2.12, representing a decline of 21.77% ($0.59).
The stock traded between $1.96 and $2.90 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 65.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.2%
BIAF is currently trading at $2.12, placing it 0.2% of the way from its 52-week low of $1.96 to its 52-week high of $80.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of bioAffinity Technologies, Inc. (BIAF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to BIAF, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between BIAF shares and USD.
BIAF Shares to USD
1.00 BIAF shares = 2.124 USD
Calculations are estimates based on the latest available price and are for reference only.